BAJAJ BROKING
Sun Pharma reported strong Q2 FY24-25 results with consolidated revenue of ₹13,264 Cr, up 10.5% YoY, and Profit After Tax (PAT) of ₹3,040 Cr, a 28% YoY growth. The company achieved significant growth across multiple regions, especially in the US and specialty segments.
Sun Pharma’s Q2 FY25 results show impressive performance, with revenue of ₹13,264 Cr and PAT of ₹3,040 Cr, highlighting the company’s strategic focus on growth in both domestic and international markets. The quarter witnessed robust sales in India and the US, supported by specialty product performance.
Financial Metric | Q2 FY25 | Q2 FY24 | YoY Growth |
Revenue from Operations (₹ Cr) | 13,264 | 12,003 | 10.50% |
US Formulations Revenue (USD Mn) | 517 | 430 | 20.30% |
India Formulations Revenue (₹ Cr) | 4,265 | 3,842 | 11% |
Employee Benefits Expense (₹ Cr) | 2,478 | 2,364 | 4.80% |
R&D Expenses (₹ Cr) | 793 | 773 | 2.50% |
EBITDA (₹ Cr) | 3,939 | 3,177 | 23.90% |
EBITDA Margin (%) | 29.6 | 26.5 | +3.1 pp |
PAT (₹ Cr) | 3,040 | 2,375 | 28% |
Earnings Per Share (EPS) (₹) | 12.7 | 9.9 | 28.30% |
In Q2 FY25, India Formulations led domestic revenue growth with ₹4,265 Cr, an 11% YoY increase, supported by new product launches. The US Formulations segment achieved $517 Mn in revenue, driven by specialty products and market expansion. The API segment reported external sales of ₹534 Cr, reflecting a 7.4% increase.
Sun Pharma’s results are in line with sector expectations, especially in the US formulations segment, showcasing resilience and strong demand. The company’s sustained revenue and PAT growth positions it favorably among industry peers, supported by strategic investments in R&D.
Dilip Shanghvi, Chairman and Managing Director, highlighted, “Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercializing late-stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market.”
Sun Pharma’s Q2 FY25 results underscore a strong operational and financial performance with revenue of ₹13,264 Cr and PAT of ₹3,040 Cr. The company’s continued focus on innovation and expansion in specialty and emerging markets sets a promising outlook for the future.
Check out Sun Pharma's past performances in previous quarters and financial years.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Morgan Stanley Acquires 1.4 Crore PNB Housing Finance Shares for ₹1,336 Crore
14 Nov, 2024 | 2 Min. read
Tata Power Commissions 126 MW Floating Solar Project in Madhya Pradesh
14 Nov, 2024 | 2 Min. read
Cipla Receives US FDA Form 483 with Eight Observations at Bengaluru Unit
14 Nov, 2024 | 2 Min. read
Varun Beverages Opens ₹5,500 Crore QIP, Sets Floor Price at ₹594.56
14 Nov, 2024 | 2 Min. read
NTPC Green Energy IPO: Price Band Set at ₹102-108 Per Share
14 Nov, 2024 | 2 Min. read
Commodities Market Today | Gold Falls for Fourth Session, Oil Rebounds on Short-Covering
14 Nov, 2024 | 1 Min. read
Share Market Today | Gift Nifty Indicates Flat Start for Indian Market Amid Mixed Cues
14 Nov, 2024 | 4 Min. read
Gold Rate Today | Gold Prices Fall for Fourth Straight Session Amid Dollar Gains
14 Nov, 2024 | 2 Min. read
Hindustan Aeronautics Limited Q2 Results FY24-25 Preview | Estimate
14 Nov, 2024 | 1 Min. read
Hero MotoCorp Q2 Results FY24-25 Preview | Estimate
14 Nov, 2024 | 1 Min. read
Samvardhan Motherson International Q2 Results FY24-25 Preview | Estimate
14 Nov, 2024 | 1 Min. read
Grasim Q2 Results FY24-25 Preview | Estimate
14 Nov, 2024 | 1 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading